Competent Cells

Competent Cells

Global Competent Cells Market to Reach $3 Billion by 2027

Amid the COVID-19 crisis, the global market for Competent Cells estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$3 Billion by 2027, growing at aCAGR of 8.8% over the period 2020-2027. Chemically Competent Cells, one of the segments analyzed in the report, is projected to record 8.5% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Electrocompetent Cells segment is readjusted to a revised 9.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $490.7 Million, While China is Forecast to Grow at 8.2% CAGR

The Competent Cells market in the U.S. is estimated at US$490.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$519.3 Million by the year 2027 trailing a CAGR of 8.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.2% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Select Competitors (Total 46 Featured) -

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GenScript Biotech Corporation
  • Illumina, Inc.
  • Merck KgaA
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Promega Corporation
  • Qiagen NV
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Zymo Research Corporation
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Clean-Label Starch Innovations
Chemically Competent Cells Segment Dominate in North America
Drivers & Restrains Summarized for Competent Cells Market
Cloning is Expected to Take the Largest Share of Competent Cells Market
Competent Cells Growth Outlook
Competent Cells Application Trends
Academic and Research Institutes Emerge as Largest End Users of Competent Cells Market
Leading Players in competent cells market
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advancements in Molecular Cloning Drives Competent Cell Market
Drivers and Restraints Summarised
SGI-DNA Inc has Launched Vmax™ Express Chemically Competent Cells .
Increasing Research on Cloning Demands Competent Cells Requirement
Increasing Intensity of Research and Technological Advancements Drives Market
Expanding Use of Protein Expression in the Production of Therapeutic Proteins Ranging from Insulin, Interferons & Interleukins to Drive Demand for Competent Cells: Global Market for Protein Expression (In US$ Million) for the Years 2017, 2019 & 2022
As the Foundation for Modern Biomolecular Research, Importance of Recombinant Proteins Spurs Demand for Competent Cells
Expanding Use of Protein Expression in the Production of Therapeutic Proteins Ranging from Insulin, Interferons & Interleukins to Drive Demand for Competent Cells: Global Market for Protein Expression (In US$ Million) for the Years 2017, 2019 & 2022
As Molecular Engineering Takes Huge Strides Forward in Manipulating & Harnessing the DNA for the Production of More Potent Therapies, Poised to Benefit are Ready-to-Use Competent Cells
Escherichia coli, the Most Widely Used Organism in the Expression of Cloned Proteins
Need for DNA Library Construction in Molecular Cloning Benefits Demand for Competent Cells
Need for Faster Characterization Proteins & More Efficient Protein Expression Spurs the Use of Competent Cells
Rise of Protein Expression Services Offering Flexible, Low-Cost Production of High-Quality, Bioactive Recombinant Proteins, Bodes Well for Market Growth
Higher Transformation Efficiencies Give Electroporation an Edge Over Chemical Methods
Heat Shock Treatment for Transformation of Competent Cells, Another Popular Method
Increased Investments in Life Sciences Research to Expand the Addressable Market Opportunity for Competent Cells
Rising Global Pharmaceutical R&D Offers a Fertile Environment for the Growth in Demand for Competent Cells: Global Pharmaceutical R&D (In US$ Billion) for the Years 2017, 2019, 2022 and 2024
Continuous Developments in Chemical Transformation Technologies to Benefit Market Growth
Rise in Non-Communicable Diseases, a Key Macro Trend Shaping Demand for Recombinant Enzymes & Proteins in Drug Discovery
Mind Bending Economic Burden of Noncommunicable Diseases (NCDs) Drives Urgent Investments in Drug Research & Development, Opening Up Opportunities for Competent Cells in Mass Production of Therapeutic Proteins: Cumulative Global Burden of NCDs (In US$ Trillion) for the Period 2011-2030
Cell Free Protein Expression & the Accompanying Promise of the Development of a Versatile Mass Production System for Protein Expression to Benefit Market Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Current & Future Analysis for Competent Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World 7-Year Perspective for Competent Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
TABLE 3: World Current & Future Analysis for Chemically Competent Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 4: World 7-Year Perspective for Chemically Competent Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
TABLE 5: World Current & Future Analysis for Electrocompetent Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 6: World 7-Year Perspective for Electrocompetent Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
TABLE 7: World Current & Future Analysis for Cloning by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World 7-Year Perspective for Cloning by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
TABLE 9: World Current & Future Analysis for Protein Expression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 10: World 7-Year Perspective for Protein Expression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
TABLE 11: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 12: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
TABLE 13: World Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World 7-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
TABLE 15: World Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 16: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
TABLE 17: World Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 18: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
TABLE 19: USA Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 20: USA 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 21: USA Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 22: USA 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 23: USA Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 24: USA 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
CANADA
TABLE 25: Canada Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 26: Canada 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 27: Canada Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 28: Canada 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 29: Canada Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 30: Canada 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
JAPAN
TABLE 31: Japan Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 32: Japan 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 33: Japan Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 34: Japan 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 35: Japan Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 36: Japan 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
CHINA
TABLE 37: China Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: China 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 39: China Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 40: China 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 41: China Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 42: China 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
EUROPE
TABLE 43: Europe Current & Future Analysis for Competent Cells by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 44: Europe 7-Year Perspective for Competent Cells by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
TABLE 45: Europe Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 46: Europe 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 47: Europe Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 48: Europe 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 49: Europe Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: Europe 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
FRANCE
TABLE 51: France Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 52: France 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 53: France Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 54: France 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 55: France Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: France 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
GERMANY
TABLE 57: Germany Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 58: Germany 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 59: Germany Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 60: Germany 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 61: Germany Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: Germany 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
ITALY
TABLE 63: Italy Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 64: Italy 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 65: Italy Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 66: Italy 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 67: Italy Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: Italy 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
UNITED KINGDOM
TABLE 69: UK Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 70: UK 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 71: UK Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 72: UK 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 73: UK Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 74: UK 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
REST OF EUROPE
TABLE 75: Rest of Europe Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 76: Rest of Europe 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 77: Rest of Europe Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 78: Rest of Europe 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 79: Rest of Europe Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: Rest of Europe 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
ASIA-PACIFIC
TABLE 81: Asia-Pacific Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 82: Asia-Pacific 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 83: Asia-Pacific Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 84: Asia-Pacific 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 85: Asia-Pacific Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: Asia-Pacific 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
REST OF WORLD
TABLE 87: Rest of World Current & Future Analysis for Competent Cells by Type - Chemically Competent Cells and Electrocompetent Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 88: Rest of World 7-Year Perspective for Competent Cells by Type - Percentage Breakdown of Value Sales for Chemically Competent Cells and Electrocompetent Cells for the Years 2020 & 2027
TABLE 89: Rest of World Current & Future Analysis for Competent Cells by Application - Cloning, Protein Expression and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 90: Rest of World 7-Year Perspective for Competent Cells by Application - Percentage Breakdown of Value Sales for Cloning, Protein Expression and Other Applications for the Years 2020 & 2027
TABLE 91: Rest of World Current & Future Analysis for Competent Cells by End-Use - Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: Rest of World 7-Year Perspective for Competent Cells by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs) for the Years 2020 & 2027
IV. COMPETITION
Total Companies Profiled: 46

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook